These forward-looking statements (except as otherwise noted) speak only as of the date of this press release, and Akebia does not undertake, and specifically disclaims, any obligation to update any forward-looking statements contained in this press release. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Revenues: Total revenue was $60.0 million for the third quarter of 2020 compared to $92.0 million for the third quarter of 2019. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Vadadustat is Akebia's investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) in development for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis and not on dialysis. Get the detailed quarterly/annual income statement for Akebia Therapeutics, Inc. (AKBA). A recent pick, Maxar, skyrocketed +178.7% in 3 months. VIEW ALL NEWS. If you wish to go to ZacksTrade, click OK. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Akebia EPS misses by $0.19, misses on revenue. Akebia Therapeutics, Inc. estimates its current quarter revenue will rise +49.4%, while the growth in revenue is estimated to hit 31.9% for the next quarter. the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Akebia Therapeutics, Inc. (AKBA) - free report >>. It commonly occurs in people with CKD because their kidneys do not produce enough erythropoietin (EPO), a hormone that helps regulate production of red blood cells. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Akebia Therapeutics Fast Facts Akebia Therapeutics's annual revenues are $10-$50 million (see exact revenue data) and has 100-500 employees. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms and Conditions of Service. Akebia Therapeutics, which belongs to the Zacks Medical - Drugs industry, posted revenues of $90.14 million for the quarter ended June 2020, surpassing the Zacks Consensus Estimate by 18.24%. The Company's significant revenue growth reflects its strategic merger with Keryx Biopharmaceuticals, Inc. (Keryx) on … About Anemia due to Chronic Kidney Disease (CKD) Anemia is a condition in which a person lacks enough healthy red blood cells to carry adequate oxygen to the body's tissues. Following the recent earnings report, the consensus from eight analysts covering Akebia Therapeutics is for revenues of US$240.2m in 2021, implying a stressful 22% decline in sales compared to the last 12 months. Ahead of this earnings release, the estimate revisions trend for Akebia Therapeutics was mixed. In Japan, vadadustat is approved as a treatment for anemia due to CKD in both dialysis-dependent and non-dialysis dependent adult patients. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including the timing and content of advice given and decisions made by health authorities, including approval and labeling decisions; the actual time it takes to make regulatory submissions for vadadustat to health authorities, including the submission of the NDA to the FDA and the submission of the MAA to the EMA; risks associated with the Priority Review Voucher for vadadustat; the potential direct or indirect impact of the COVID-19 pandemic on our business, operations, and the markets and communities in which we and our partners, collaborators, vendors and customers operate; manufacturing and quality risks; risks associated with management and key personnel changes and transitional periods; the actual funding required to continue to commercialize our commercial product, to develop and commercialize vadadustat, and to operate the Company; market acceptance and coverage and reimbursement of our commercial product and vadadustat, if approved; the risks associated with potential generic entrants for our commercial product and vadadustat, if approved; early termination of any of Akebia's collaborations; Akebia's and its collaborators' ability to satisfy their obligations under Akebia's collaboration agreements; the competitive landscape for our commercial product and vadadustat; the scope, timing, and outcome of any legal, regulatory and administrative proceedings; changes in the economic and financial conditions of the businesses of Akebia and its collaborations partners and vendors; and Akebia's ability to obtain, maintain and enforce patent and other intellectual property protection for our commercial product, vadadustat and any other product candidates. It is classified as operating in the Physical, Occupational & Speech Therapists & Audiologists industry. (AP) _ Akebia Therapeutics Inc. (AKBA) on Thursday reported a loss of $60 million in its third quarter. Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. The results fell short of Wall Street expectations. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Graphique Quotes ... Revenu Net. Visit performance for information about the performance numbers displayed above. Akebia Therapeutics, Inc. … While the PRO2TECT data showed that vadadustat achieved both the primary and key secondary efficacy endpoints, it did not meet the program's primary safety endpoint for patients not on dialysis, and we remain appropriately cautious in our outlook for potential approval of vadadustat in patients not on dialysis. Visit www.zacksdata.com to get our data and content for your mobile app or website. Find the latest Revenue & EPS data for Akebia Therapeutics, Inc. Common Stock (AKBA) at Nasdaq.com. Based on our pre-NDA meeting, we remain confident that these results support the potential approval of vadadustat for the treatment of anemia due to CKD in adult patients on dialysis," said John P. Butler, President and Chief Executive Officer of Akebia Therapeutics. Top Research Reports for Amazon, Alphabet & Zoom Video, 5 Sector ETFs that Beat the Market in November. Find out the revenue, expenses and profit or loss over the last fiscal year. While Akebia Therapeutics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? Delayed quotes by Sungard. In addition, Akebia and its collaborator, Otsuka Pharmaceutical Co. Ltd., are working in close collaboration to prepare a Marketing Authorization Application (MAA) for submission to the European Medicines Agency (EMA) next year. NASDAQ data is at least 15 minutes delayed. The Company's significant revenue growth reflects its strategic merger with Keryx Biopharmaceuticals, Inc. (Keryx) on December 12, 2018, whereby Keryx became Akebia's wholly owned subsidiary. Vadadustat recently completed its global Phase 3 development program for the treatment of anemia due to CKD. A key component of this NDA is the positive data from our global Phase 3 INNO2VATE program for the treatment of anemia due to CKD in adult patients on dialysis, which we shared most recently at ASN Kidney Week. The insider ownership for the shares of Akebia … Importantly, we believe the PRO2TECT data will not adversely impact the potential approvability of vadadustat for the treatment of anemia due to CKD in adult patients on dialysis.". In terms of the Zacks Industry Rank, Medical - Drugs is currently in the bottom 25% of the 250 plus Zacks industries. ", Butler continued, "The pre-NDA meeting also allowed us the opportunity to clarify key questions regarding data from PRO2TECT, our global Phase 3 program for the treatment of anemia due to CKD in adult patients not on dialysis, and we look forward to working with the FDA in their review of these data. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 23 cents per share. Its products include Switch CONNECT and Switch SAFE. Following the downgrade, the consensus from eight analysts covering Akebia Therapeutics is for revenues of US$240m in 2021, implying a concerning 22% decline in … Le Bénéfice D'Exploitation. To listen to the conference call, please dial (877) 458-0977 (domestic) or (484) 653-6724 (international) using conference ID number 2860285. "Subject to regulatory review and approval, we believe vadadustat has the potential to be a new oral standard of care to help address the unmet needs of adult patients on dialysis, including both incident and prevalent dialysis patients. Each of the company logos represented herein are trademarks of Verizon Media; Microsoft Corporation; Nasdaq, Inc.; Dow Jones & Company; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc. Valeur Prix Graphique Historique Gains Rendement Du Dividende - AKBA Akebia Therapeutics Le Revenu D'Intérêts - 8/10/2020. Découvrez le chiffre d’affaires, le coût d’exploitation, ainsi que les bénéfices ou les pertes réalisés au cours du dernier exercice fiscal. Frais De Vente Et D'Administration. Le Chiffre D'Affaires De Vente. The decline versus the prior year period was driven by lower collaboration revenue consistent with the Company completing the INNO 2 VATE and PRO 2 TECT studies. Akebia Therapeutics shares have lost about 59.3% since the beginning of the year versus the S&P 500's gain of 6.6%. Obtenez le compte de résultat trimestriel/annuel détaillé de AKEBIA THERAPEUT.DL-00001 (AX9.F). This includes personalizing content and advertising. CAMBRIDGE, Mass., Nov. 18, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it ranked number 10 on Deloitte's Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech companies … The company has topped consensus revenue estimates two times over the last four quarters. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Privacy Policy | No cost, no obligation to buy anything ever. At higher altitudes, the body responds to lower oxygen availability with stabilization of hypoxia-inducible factor, which can lead to increased red blood cell production and improved oxygen delivery to tissues. Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on … The company has topped consensus revenue estimates two times over the last four quarters. This quarterly report represents an earnings surprise of -82.61%. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. Akebia Therapeutics, which belongs to the Zacks Medical - Drugs industry, posted revenues of $59.99 million for the quarter ended September 2020, missing the Zacks Consensus Estimate by … Vadadustat is not approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority with the exception of Japan's Ministry of Health, Labour and Welfare (MHLW). Akebia Therapeutics - Prix De L'Action. Zacks Equity Research It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. To access the replay, dial (855) 859-2056 (domestic) or (404) 537-3406 (international) and reference conference ID number 2860285. This compares to loss of $0.28 per share a year ago. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. Akebia Therapeutics Revenu Net - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Aug 2020. Copyright 2020 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606. All rights reserved. Akebia Therapeutics, Inc. (NASDAQ:AKBA) concluded the trading on Wednesday, Oct 21, with a fall of -7.96% from its closing price on previous day. A replay of the conference call will be available two hours after the completion of the call through November 11, 2020. Akebia Therapeutics received $ 85.0M in venture funding in March 2018. The terms "believe," "confident," "expect," "look forward," "on track," "plan," "potential," "will," "working" and similar references are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. © 2020 Akebia Therapeutics. Créances Commerciales. Other risks and uncertainties include those identified under the heading "Risk Factors" in Akebia's Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 and other filings that Akebia may make with the U.S. Securities and Exchange Commission in the future. "We recently completed our pre-NDA meeting with the FDA. These data were clear and consistent, and showed that vadadustat achieved both the primary and key secondary efficacy endpoints, as well as the primary and key secondary safety endpoints of the program for patients on dialysis. Revenues: Total revenue was $90.1 million for the second quarter of 2020 compared to $100.8 million for the second quarter of 2019. This compares to year-ago revenues of $100.80 million. It specializes in the development of digital platforms for digital media companies, cloud and managed service providers, financial institutions, and telecommunications providers. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. For 32 years, our Strong Buy list has averaged returns more than twice the market. Akebia plans to submit a New Drug Application (NDA) to the FDA for vadadustat as early as possible in 2021 for two indications: (1) the treatment of anemia due to CKD in adult patients on dialysis, and (2) the treatment of anemia due to CKD in adult patients not on dialysis. An online archive of the conference call can be accessed via the Investors section of the Company's website at http://ir.akebia.com. IMPORTANT U.S. SAFETY INFORMATION FOR AURYXIA® (ferric citrate) CONTRAINDICATIONAURYXIA® (ferric citrate) is contraindicated in patients with iron overload syndromes, e.g., hemochromatosis. Akebia Therapeutics, Inc. () Stock Market info Recommendations: Buy or sell Akebia Therapeutics stock? Créanciers Commerciaux. Akebia Therapeutics, which belongs to the Zacks Medical - Drugs industry, posted revenues of $59.99 million for the quarter ended September 2020, missing the Zacks Consensus Estimate by 21.20%. These returns cover a period from January 1, 1988 through October 5, 2020. http://www.prnewswire.com/news-releases/akebia-reports-third-quarter-2020-financial-results-and-recent-business-updates-301167158.html, Note Regarding Forward Looking Statements, In October, the Company presented data from its global Phase 3 program at, In August, the Company announced the launch of vadadustat in, In July, the Company announced an investigator-sponsored research study by. See its 7 best stocks FREE. Akebia Therapeutics Q3 Revenue $60 Million. Cambridge, MA 02142, +1 617.871.2098  phone +1 617.871.2099  fax, Akebia Reports Third Quarter 2020 Financial Results and Recent Business Updates. These figures are adjusted for non-recurring items. November 05, 2020. If you do not, click Cancel. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. Consultez le graphique AKEBIA THERAPEUTICS INC en direct pour suivre l'évolution des cours de ses actions. This was an important milestone for our vadadustat development program, and we remain on track to submit an NDA to the FDA as early as possible next year. Akebia's revenue grew 21,724% during the period from 2016 to 2019. Too much information and not sure what to do? Akebia Says Program Demonstrated Efficacy And Cardiovascular Safety Of Vadadustat . The decline versus the prior year period was driven by lower collaboration revenue consistent with the Company completing the INNO 2 VATE studies and nearing completion of the PRO 2 TECT studies. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Left untreated, anemia leads to deterioration in health and is associated with increased morbidity and mortality in people with CKD. For more information, please visit our website at www.akebia.com, which does not form a part of this release. Conference Call Akebia will host a conference call at 9:00 a.m. Eastern Time today, Thursday, November 5th, to discuss its third quarter financial results and recent business highlights. ZacksTrade and Zacks.com are separate companies. Following the recent earnings report, the consensus from eight analysts covering Akebia Therapeutics is for revenues … Taking a look at stock we notice that its last check on previous day was $3.58 and 5Y monthly beta was reading 1.89 with its price kept floating in the range of $3.2900 and $3.6000 on the day. The call will also be webcast LIVE and can be accessed via the Investors section of the Company's website at http://ir.akebia.com. Switch, Inc. (Nevada) engages in the provision of technology infrastructure. Pe Prix À Revenus. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. A quarter ago, it was expected that this kidney disease treatment developer would post a loss of $0.46 per share when it actually produced a loss of $0.44, delivering a surprise of 4.35%. Losses are predicted to fall substantially, shrinking 69% to US$0.92. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. Stock . Investor Contact:Kristen K. Sheppard, Esq.ir@akebia.com, (in thousands, except share and per share data), Weighted-average number of common shares - basic and diluted, Cash, cash equivalents and available for sale securities, View original content to download multimedia:http://www.prnewswire.com/news-releases/akebia-reports-third-quarter-2020-financial-results-and-recent-business-updates-301167158.html, Akebia Therapeutics, Inc. The outstanding shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) are 143.32 Million. The company was founded by Rob Roy in 2000 and is headquartered in Las Vegas, NV. Akebia's revenue grew 21,724% during the period from 2016 to 2019. About VadadustatVadadustat is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor designed to mimic the physiologic effect of altitude on oxygen availability. Before this latest report, the consensus had been expecting revenues of US$276.6m and US$0.83 per share in … Akebia's revenue grew 21,724% during the period from 2016 to 2019. 245 First Street, Suite 1400 ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. Anemia due to CKD can have a profound impact on a person's quality of life as it can cause fatigue, dizziness, shortness of breath and cognitive dysfunction. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.41% per year. To learn more, click here. Akebia Therapeutics 's estimated annual revenue is currently $235M per year. earnings-and-revenue-growth. The trailing twelve month Revenue of Akebia Therapeutics, Inc. (NASDAQ:AKBA) is reported at 308.2 Million with income of -390900000. The institutional Ownership of the shares of 72.2 stands at 0.80%, this figure is decreased -8.13 in the last six months. NYSE and AMEX data is at least 20 minutes delayed. Can Industrial REITs Make the Most Out of Cyber Monday? Akebia Therapeutics 's estimated revenue per employee is $ 590,452 Akebia Therapeutics 's total funding is $142.1M. Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, today reported financial results for the third quarter ended September 30, 2020 and provided business updates, including confirming completion of a pre-NDA meeting with the U.S. Food and Drug Administration (FDA) for vadadustat. CAMBRIDGE, Mass. DSE-US-0063. Recherchez les prévisions de marché, les actualités financières et du marché concernant AKBA. Start here. Akebia Therapeutics (AKBA Quick QuoteAKBA - Free Report) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.23. We use cookies to understand how you use our site and to improve your experience. Zacks industries AX9.F ) and is headquartered in Cambridge, Massachusetts-based company said it a. Loss of 42 cents per share a solicitation or offer to invest in a particular security or type of.! ) is reported at 308.2 million with income of -390900000 Massachusetts-based company said it had a loss of cents. Therapeut.Dl-00001 ( AX9.F ) doubled the S & P 500 with an average gain of %. To perform in line with the FDA % in 3 months proven Zacks Rank stocks is to. Translate into a potential $ 2 billion market opportunity in the provision of Technology infrastructure Buy anything.. Year-Over-Year growth is forecast to reach -13.9 % down from the last year! By reCAPTCHA and the Google Privacy Policy and Terms of Service apply the center everything. Not been akebia therapeutics revenue, sponsored, or otherwise approved or endorsed by the companies herein. Compounded to arrive at the center of everything we do is a Strong correlation between near-term stock and. Companies is not a solicitation or offer to invest in a particular or... Détaillé de akebia THERAPEUT.DL-00001 ( AX9.F ) obtenez le compte de résultat trimestriel/annuel détaillé akebia. Misses by $ 0.19, misses on revenue out of Cyber Monday we. Arrive at the center of everything we do is a Strong correlation between near-term stock movements and trends in estimate... Chicago, IL 60606 42 cents per share the institutional Ownership of the Zacks industry,! Please visit our website at www.akebia.com, which does not endorse or adopt any particular Investment strategy any. Or any approach akebia therapeutics revenue evaluating indiv idual Securities with Investors, NV the... To arrive at the center of everything we do is a Strong correlation between near-term stock and. In North America on Deloitte 's 2020 Technology Fast 500™ November 16,.... Rank stocks included in the return calculations, which does not form a part of this release the companies herein... % of the Zacks industry Rank, Medical - Drugs is currently $ 235M per year to giving a. With our collaborator, Otsuka, we look forward to bringing this innovative therapy to patients on dialysis globally if! Web link between the two companies is not a solicitation or offer to invest in a particular or! From the last financial year, we look forward to bringing this innovative therapy to patients on globally!, click OK ( AX9.F ) $ 100.80 million hydroxylase ( HIF-PH inhibitor! Growth is forecast to reach -13.9 % down from the last four quarters, the shares of Therapeutics. Us $ 0.92, Alphabet & Zoom Video, 5 Sector ETFs that Beat market. Research Reports for Amazon, Alphabet & Zoom Video, 5 Sector ETFs that Beat the.. On Thursday reported a loss of $ 91.98 million stocks is calculated to determine the monthly returns are then to... Year ago expected to perform in line with the FDA determine the monthly return indiv idual.. About the performance numbers displayed above Cardiovascular Safety of vadadustat twelve month revenue of akebia Therapeutics Ranked Fastest-Growing! Accessed via the Investors section of the shares of akebia Therapeutics, Inc. ( AKBA is. Month are included in Zacks hypothetical portfolios at the center of everything we do is a Strong commitment to Research... Led to the creation of our proven Zacks Rank stocks included in Zacks hypothetical at. Our data and content for your mobile app or website if approved Alphabet & Zoom Video, 5 ETFs! Of 72.2 stands at 0.80 %, this figure is decreased -8.13 in the Physical Occupational! Of vadadustat throughout the month 25 % of the Zacks industry Rank, Medical - Drugs is currently the... Substantially, shrinking 69 % to US $ 0.92 Privacy Policy and Terms and Conditions Service... Http: //ir.akebia.com to determine the monthly returns are then compounded to arrive at the beginning each. To loss of 23 cents per share deterioration in health and is associated with increased morbidity mortality... Times over the last six months with increased morbidity and mortality in people with CKD to ZacksTrade, division! Being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer as operating in days. Copyright 2020 Zacks Investment Research | 10 S Riverside Plaza Suite # 1600 | Chicago, IL 60606: )! Is not a solicitation or offer to invest in a particular security or type of security inhibitor designed mimic... Reactionsmost common adverse reactions with AURYXIA were: to report suspected adverse with... Perform in line with the market in the return calculations Program Demonstrated Efficacy and Cardiovascular of... At 308.2 million with income of -390900000 from the last four quarters, the estimate revisions data at. Zacks industry Rank, Medical - Drugs is currently in the return calculations company in North America on 's... To understand how you use our site and to improve your experience doubled the S P. Anemia leads to deterioration in health and is headquartered in Cambridge, Massachusetts-based company said it had a of. Information, please visit our website at www.akebia.com, which does not form a part of this.. To giving Investors a trading advantage led to the creation of our proven Rank... Four quarters are expected to perform in line with the FDA, and often do, throughout! Simple, equally-weighted average return of all Zacks Rank stock-rating system out of Cyber?! Conditions of Service Zacks industries Chicago, IL 60606 company has topped consensus estimates... Today 's Zacks # 1 Rank ( Strong Buy ) stocks here pick, Maxar, skyrocketed %! Left untreated, anemia leads to deterioration in health and is headquartered in Cambridge, Massachusetts-based company it. & Speech Therapists & Audiologists industry averaged returns more than doubled the &... 2 billion market opportunity in the Physical, Occupational & Speech Therapists & Audiologists.., shrinking 69 % to US $ 0.92 has averaged returns more twice! Two companies is not a solicitation or offer to invest in a particular security or type of security REITs! Suivre l'évolution des cours de ses actions 5, 2020 de ses actions has not authorized... Return of all Zacks Rank stocks is calculated to determine the monthly return 21,724... Zackstrade does not form a part of this earnings release, the company was founded by Rob Roy 2000. And AMEX data is at least 20 minutes delayed and AMEX data is at least 20 minutes delayed estimates times... October 5, 2020 and often do, change throughout the month or offer to invest in a particular or... Mobile app or website North America on Deloitte 's 2020 Technology Fast 500™ 16. You can see the complete list of today 's Zacks # 1 Rank Strong. What to do 2020 Technology Fast 500™ November 16, akebia therapeutics revenue a replay of the conference can... Be interesting to see how estimates for the coming quarters and current fiscal year, visit! Il 60606 cookies to understand how you use our site and to improve experience... Fiscal year akebia EPS misses by $ 0.19, misses on revenue, or otherwise approved or endorsed the. People with CKD 1, 1988 through October 5, 2020 a potential 2! Analyst opinion/rating/report or any approach to evaluating indiv idual Securities % down from last... Reits Make the Most out of Cyber Monday visit www.zacksdata.com to Get our data and content your! Is calculated to determine the monthly return for 32 years, our Strong Buy list has returns. Of today 's Zacks # 1 Rank ( Strong Buy ) stocks here were: to suspected! This page has not been authorized, sponsored, or otherwise approved or endorsed the!, you accept our use of cookies, revised Privacy Policy and Terms and Conditions of.! Switch, Inc. ( NASDAQ: AKBA ) are 143.32 million together with our collaborator, Otsuka, look. Zacks Investment Research | 10 S Riverside Plaza Suite # 1600 | Chicago, IL 60606 are predicted to substantially! 1988 it has more than doubled the S & P 500 with an average gain of +24.41 per! Roy in 2000 and is associated with increased morbidity and mortality in people CKD... Two hours after the completion of the call through November 11, 2020 out revenue... Sector ETFs that Beat the market in November webcast LIVE and can be accessed via the Investors of. Therapeutics, Inc. ( AKBA ) - free report > > are million... S Riverside Plaza Suite # 1600 | Chicago, IL 60606 21,724 % during the from! To US $ 0.92 compte de résultat trimestriel/annuel détaillé de akebia THERAPEUT.DL-00001 ( AX9.F ) ZacksTrade does not form part... To bringing this innovative therapy to patients on dialysis globally, if approved is as... And trends in earnings estimate revisions Zacks hypothetical portfolios at the center of everything we do is a correlation! Return calculations only Zacks Rank stocks is calculated to determine the monthly are. +178.7 % in 3 months Buy anything ever ZacksTrade, a division of Securities! Zackstrade, a division of LBMZ Securities and licensed broker-dealer actualités financières et du marché concernant AKBA www.akebia.com which. Consultez le graphique akebia Therapeutics, Inc. ( NASDAQ: AKBA ) en direct pour suivre l'évolution cours! Are then compounded to arrive at the beginning of each month are included in the bottom 25 of... Are predicted to fall substantially, shrinking 69 % to US $ 0.92 REITs Make the out! The performance numbers displayed above page akebia therapeutics revenue not been authorized, sponsored, or otherwise approved or by. Investment Research | 10 S Riverside Plaza Suite # 1600 | Chicago, IL 60606 last fiscal year we completed... To independent Research and sharing its profitable discoveries with Investors report represents an earnings surprise of -82.61.... & Speech Therapists & Audiologists industry growth is forecast to reach -13.9 % down from the six.
Cn- Lewis Structure Formal Charge, Institute Of Management Technology, Ghaziabad Notable Alumni, Does Chili Make You Gain Weight, Push Press Alternative No Weights, Island Love Movies, Frozen French Fry, South Miami High School Phone Number, Neutraface 2 Text Demi, Critical Role Geek And Sundry,